Kyle Doherty

Kyle Doherty joined MJH Life Sciences in 2021 and is the lead editor for Oncology Fellows. He also produces print content for OncologyLive, as well as news and conference updates for OncLive.com. Email: kdoherty@mjhlifesciences.com

Articles

Camrelizumab Plus Famitinib Extends PFS vs Chemotherapy in First-Line Metastatic Cervical Cancer

October 20th 2025

Camrelizumab plus famitinib led to superior PFS and OS outcomes vs chemotherapy in frontline recurrent/metastatic cervical cancer.

Telisotuzumab Adizutecan Demonstrates Activity, Tolerability in Locally Advanced/Metastatic PDAC

October 20th 2025

Telisotuzumab adizutecan displayed early activity in locally advanced/metastatic PDAC.

Ivonescimab Plus Chemo Might Be a New SOC in Advanced Squamous NSCLC

October 19th 2025

Ivonescimab plus chemotherapy improved PFS and response rates vs tislelizumab in advanced squamous NSCLC, with a manageable safety profile.

Chemotherapy Plus Durvalumab, Bevacizumab, and Olaparib Fails to Offer OS Benefit in Newly Diagnosed Non-tBRCA–Mutated Ovarian Cancer

October 19th 2025

Chemotherapy plus durvalumab, bevacizumab, and olaparib did not significantly prolong OS in non-tBRCA-mutated ovarian cancer.

Atezolizumab Plus Chemotherapy Demonstrates Noninferior Survival Vs Chemotherapy Alone in Advanced/Recurrent Endometrial Cancer

October 19th 2025

The addition of atezolizumab to chemotherapy demonstrated noninferior survival vs chemotherapy alone in advanced or recurrent endometrial cancer.

Enzalutamide Plus Leuprolide Yields OS Benefit in High-Risk, Biochemically Recurrent Prostate Cancer

October 19th 2025

Enzalutamide plus leuprolide acetate led to a 40.3% lower risk of death vs leuprolide acetate alone in high-risk, biochemically recurrent prostate cancer.

Capivasertib Plus Abiraterone Acetate, Prednisone, and ADT Extends rPFS in PTEN-Deficient HSPC

October 19th 2025

Capivasertib plus abiraterone acetate, prednisone, and androgen deprivation therapy was active in PTEN-deficient de novo metastatic HSPC.

Sac-TMT Yields PFS Benefit Over Chemotherapy in Pretreated HR+, HER2– Metastatic Breast Cancer

October 19th 2025

Sac-TMT bested chemotherapy in terms of PFS in previously treated HR+, HER2– metastatic breast cancer.

Invikafusp Alfa Boasts High Disease Control Rate in Checkpoint Inhibitor–Resistant Solid Tumors

October 18th 2025

Invikafusp alfa demonstrated early signals of antitumor activity across a range of biomarker-enriched patients with solid tumors.

Adjuvant Nivolumab Displays Long-Term Activity in Resected Melanoma

October 18th 2025

Adjuvant nivolumab significantly extended RFS vs ipilimumab in patients with resected stage IIIB to IIIC or IV melanoma.

177-Lu-edotretide Prolongs PFS Compared With Everolimus in Grade 1/2 GEP-NETs

October 18th 2025

177-Lu-edotretide significantly improved survival outcomes vs everolimus for the treatment of patients with grade 1/2 GEP-NETs.

Dato-DXd Plus Rilvegostomig Elicits Activity in Cisplatin-Ineligible or Platinum-Pretreated Urothelial Cancer

October 18th 2025

Datopotamab deruxtecan plus rilvegostomig was active in cisplatin-ineligible and platinum-pretreated locally advanced or metastatic urothelial cancer.

SunRISe-4 Data Support Role for Neoadjuvant Gemcitabine Intravesical System Plus Cetrelimab in MIBC

October 17th 2025

SunRISe-4 data show that TAR-200 and cetrelimab led to a high pCR and 12-month RFS rate in muscle-invasive bladder cancer.

Adjuvant Ribociclib Plus AI Therapy Has Long-Term Activity in HR+, HER2-Negative Early Breast Cancer

October 17th 2025

Adjuvant ribociclib plus an aromatase inhibitor was safe and displayed long-term efficacy in hormone receptor–positive, HER2-negative early breast cancer.

Durvalumab Plus FLOT Prolongs OS vs FLOT Alone in Gastric/GEJ Adenocarcinoma

October 17th 2025

The addition of durvalumab to FLOT prolonged overall survival vs FLOT alone in resectable gastric/gastroesophageal junction adenocarcinoma.

Abemaciclib Plus Endocrine Therapy Provides OS Benefit in HR+/HER2-Negative Breast Cancer

October 17th 2025

The addition of adjuvant abemaciclib to endocrine therapy provided an OS benefit vs endocrine therapy alone in hormone receptor–positive breast cancer.

Zongertinib Displays Activity in Frontline HER2-Mutated NSCLC

October 17th 2025

Zongertinib was effective for the first-line treatment of patients with treatment-naive HER2-mutated NSCLC.

Asciminib Receives Positive CHMP Opinion for Ph+ CP-CML

October 17th 2025

The EMA’s CHMP has recommended the approval of asciminib for Philadelphia chromosome–positive chronic myeloid leukemia in chronic phase.

Adjuvant Cemiplimab Recommended for European Approval in CSCC

October 17th 2025

The EMA’s CHMP has recommended the approval of adjuvant cemiplimab in CSCC at high risk of recurrence after surgery and radiation

Dr Wang on the Role of Bridging Radiotherapy Prior to CAR T-Cell Therapy in B-Cell Lymphoma

October 16th 2025

Pule Wang, MD, discusses CNS bridging radiotherapy prior to CAR T-cell therapy in B-cell lymphomas.